Alpine Biomed eyes global role with Medtronic diagnostics assets
This article was originally published in Clinica
Alpine Biomed is staking out a global leadership position in the specialty diagnostics market after completing the purchase of Medtronic's neurodiagnostic product line for an undisclosed sum on August 1. The Fountain Valley, California company gained all Medtronic neurodiagnostic equipment and accessories, including the Keypoint electromyography (EMG), Clavis hand-held EMG injection device, and needle and surface electrodes. It is Alpine's second deal with Medtronic this year: in May it purchased Medtronic's gastroenterology diagnostic product line, and this latest transaction sees Alpine acquire the whole range of diagnostics tools, ready for integration into its own portfolio for the treatment of various neuropathies.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.